



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

•	JA504705	FOR FURTHER ACTION See Notification of TExamination Report		cation of Transmittal of Interrion Report (Form PCT/IPE	ransmittal of International Preliminary (Form PCT/IPEA/416)				
•	International application No. PCT/JP 03 ()7333	International filing date (d		Priority date (day/month)					
	International Patent Classification (IPC) or national classification and IPC Int.Cl 7 C07K7/06, A61K38/08, A61K38/55, A61P1/04, A61P1/14, A61P27/02, A61P4 3/00								
	Applicant THE UNIVERSITY OF EDINBURGH								
 This international preliminary examination report has been prepared by this International Preliminary Examining and is transmitted to the applicant according to Article 36. This REPORT consists of a total of sheets, including this cover sheet. This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which amended and are the basis for this report and/or sheets containing rectifications made before this Authority 									
	70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheets.								
	3. This report contains indications relating to the following items:								
	I Basis of the report								
	II Priority								
A	III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability								
)	IV Lack of unity of invention								
	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement								
	VI Certain documents cited								
	VII Certain defects in the international application								
	VIII Certain observations on the international application								
	Date of submission of the demand		Date of completion of this report						
	13.11.2003		2005.2004						
	Name and mailing address of the IPEA/JP		Authorized office		4B 9735				
	Japan Patent Office		NORIKO MUKASA						
	3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan		Telephone No. +81-3-3581-1101 Ext. 3448						



International application No. PCT/JP 03 \(\infty 7333 \)

gard to the elements of the international application:* ne international application as originally filed ne description: ages					
ne description: ages, as originally file					
ages, as originally file					
ages, filed with the demar					
ages, filed with the letter of					
ne claims: Tos					
os, as amended (together with any statement) under Article					
os, filed with the deman					
os, filed with the letter of					
ne drawings:					
ets/figs, as originally file					
ets/figs, filed with the demar					
eets/figs, filed with the letter of					
ne sequence listing part of the description:					
ages, as originally file					
ages, filed with the deman					
ages, filed with the letter of					
te language of publication of the international application (under Rule 48.3(b)). The language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and 55.3).					
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:					
ontained in the international application in written form.					
led together with the international application in computer readable form.					
rmished subsequently to this Authority in written form.					
furnished subsequently to this Authority in computer readable form.					
The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.					
he statement that the information recorded in computer readable form is identical to the written sequence listing here furnished.					
he amendments have resulted in the cancellation of:					
the description, pages					
the claims, Nos.					
the drawings, sheets/figs					
his report has been established as if (some of) the amendments had not been made, since they have been considered to geyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**					
ment sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to ort as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17					
To to the second and a second as the second and the					



V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1.	Statement		•	-		
	Novelty (N)	Claims	1-7	_ YES		
		Claims	·	_ ио		
	Inventive step (IS)	Claims		_ YES		
		Claims	1-7	_ ио		
•	Industrial applicability (IA)	Claims	1-7	YES		
	,	Claims		_ NO		
•						

2. Citations and explanations (Rule 70.7)

D1: WO 01/62291 A1(FUSO PHARM IND LTD) 2001.08.30 D2:WO 01/47556 A1(FUSO PHARM IND LTD)2001.07.05

D3:D'Alessio S et al, Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptides., Bioorg Med hem., 1999, Vol. 7, No. 2, p. 389-94.

especially page 390 Scheme 1

D4:WO 97/25351 A2(MILLENNIUM PHARM INC)1997.07.17 ,especially page 5~7

The subject matters of claim 1 through 7 does not involve an inventive step over D1,D2, D3 and D4 for the following reasons.

D1 describes a peptide(SLIGRL-NH2) activating PAR-2 which are useful in controlling gastric hydrochloric acid secretion, promoting digestive mucous secretion, protecting gastric mucosae, repairing gastric tissues and preventing and treating gastric diseases.


D2 describes a peptide(SLIGRL-NH2) activating PAR-2 which can be used in the treatment of promoting lacrimal secretion.

D3 describes a peptide inhibitor of metaloproteinase which is modified by 2-furancarboxylic acid in the N-termini(D3 p.390 Scheme 1).

D4 describes a peptide which mimic the conserves amino acid motif LDTSL of MAdCA M-1 and which have groups (for example, aryl group)bonded to the N-and C-termini(D 4 p.5~7).

D3 and D4 disclose modifying the N-termini of peptide, and the skilled person in the art would easily conceive the idea of modifing the peptide in D1 and D2.

It would be obvious to the person skilled in the art to truncate the peptide in N-termini, and no unexpected effects are indicated except compounds which contains 2-furancarboxylic acid, Example 6,16,17, and 18.



Internal application No. PCT/JP 03 \(\lambda\)7333

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

Claim 1-7 is not supported by the description as required by Article 6 PCT. The reason therefor is the following: aryl group in claim 1 contains a lot of structure, but in the description, only a few structures are disclosed.

We searched the subject matter of claim 1-7 which is supported by the description, Z -(CH2)n represents in the example 1-18,AA1-AA2 represents Lys-Val or Arg-Leu,and R represents -OH or -NH2.